MuLBSTA Score
Not fully reviewed/validated for use with COVID-19 at this time
MuLBSTA Score: Predicts 90‑day mortality risk in patients with viral pneumonia.
Indicações de Uso
Used to stratify 90‑day mortality risk in hospitalized viral pneumonia by incorporating multilobar infiltrates, lymphopenia, bacterial coinfection, smoking status, hypertension, and age ≥60. Helps identify high‑risk patients needing closer monitoring or early escalation. Derived from a 528‑patient cohort with 14.4% mortality, showing AUROC 0.773 and outperforming CURB‑65 1.
Insights e Precauções
Indicates mortality risk in viral pneumonia but has limited validation in COVID‑19 and should not guide decisions alone. Early descriptive data suggested alignment with severe cases 1 [Level III evidence], but multiple systematic reviews show high or unclear risk of bias and unreliable performance across COVID‑19 prognostic tools 2 [Level I evidence]; 3 [Level II evidence]. Use only as supplementary context alongside clinical judgment and established predictors (e.g., age, oxygenation).